Minimal Residual Disease tests in Dubai & UAE

Compare available Minimal Residual Disease tests, their listed prices and the information provided for each option. Test selection and preparation should be discussed with your clinician.

Tests in this category

Listed price range

1,200.00–2,500.00 AED

Clinical preparation

Confirm test-specific instructions with your clinician or laboratory.

Compare available tests

Minimal Residual Disease test prices

Showing 1–4 of 4 matching tests.

Minimal Residual Disease diagnostic tests, details, and listed prices
Test and description	Specimen	Typical duration	Price	Options
TEST-958 BCR‑ABL1 Quantitative (CML MRD1) Monitoring Test This test quantifies the BCR-ABL1 fusion transcript in peripheral blood using real-time quantitative PCR standardized to the International Scale (IS). It is used for monitoring min...	Peripheral whole blood (EDTA tube)	24 hours (verbal); 36 hours (written report)	1,200.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["BCR-ABL1 fusion transcript", "Minimal Residual Disease (MRD)"] Parameters [{"name": "BCR-ABL1 transcript level", "reference_range": "Reported as a percentage on the International Scale (IS)"}] Preparation [] Indications ["Monitoring CML treatment response", "Assessing molecular remission", "Guiding TKI therapy adjustments"] Measurement technique Confirm with laboratory Codes LOINC: 5196-1 ICD-10: C92.10 Clinical summary This test quantifies the BCR-ABL1 fusion transcript in peripheral blood using real-time quantitative PCR standardized to the International Scale (IS). It is used for monitoring minimal residual disease (MRD) in patients with Chronic Myeloid Leukemia (CML).
TEST-2553 Minimal Residual Disease (MRD) Analysis for B-Cell Acute Lymphoblastic Leukemia (B-ALL) Test This test quantifies the level of residual leukemia cells in bone marrow after initial treatment.	Bone Marrow Aspirate	Next working day (sample received by 9 AM)	1,900.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Leukemic cell count", "Immunophenotype"] Parameters [{"name": "Sensitivity (Limit of Detection)", "reference_range": "0.01% (10⁻⁴) with 8–10 color panels"}] Preparation ["Provide prior immunophenotype reports", "Provide complete clinical history"] Indications ["Post-induction surveillance for B-ALL", "Risk stratification", "Guiding treatment intensification/de-escalation", "Informing stem cell transplant timing", "Relapse monitoring post-transplant"] Measurement technique Confirm with laboratory Codes LOINC: 96578-2 ICD-10: C91.00 Clinical summary This test quantifies the level of residual leukemia cells in bone marrow after initial treatment.
TEST-2556 Minimal Residual Disease (MRD) Monitoring for B-Cell Chronic Lymphocytic Leukemia (B-CLL) Test This test quantifies the level of residual B-CLL cells in bone marrow or peripheral blood after treatment.	Bone Marrow Aspirate (first pull, 3 mL, green top sodium heparin) & Peripheral Whole Blood (4 mL, 2 green top sodium heparin tubes) plus 2–3 unstained BMA or peripheral smears	3 Working Days	2,500.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Residual B-CLL cells", "Treatment response"] Parameters [] Preparation ["Provide sample time point relative to chemotherapy cycles", "Provide most recent diagnostic immunophenotype report", "Provide complete clinical history", "Provide test request form (TRF)", "Provide exact date and time of sample collection", "Provide full details of current therapy"] Indications ["Post-treatment monitoring for B-CLL", "Assessing treatment efficacy", "Predicting relapse risk"] Measurement technique Confirm with laboratory Codes LOINC: 53421-1 ICD-10: C91.1 Clinical summary This test quantifies the level of residual B-CLL cells in bone marrow or peripheral blood after treatment.
TEST-2547 Minimal Residual Disease (MRD) Monitoring for Multiple Myeloma Test This test detects and quantifies residual myeloma cells in the bone marrow after treatment using multiparametric flow cytometry.	Bone Marrow Aspirate (first pull)	3 working days	2,500.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Residual myeloma cells", "Sensitivity to therapy"] Parameters [] Preparation ["Inform physician about anti-CD38 therapy history", "Follow specific instructions from treating doctor"] Indications ["Post-treatment monitoring for multiple myeloma", "Assessing remission depth", "Guiding treatment decisions"] Measurement technique Confirm with laboratory Codes LOINC: 73753-8 ICD-10: C90.0 Clinical summary This test detects and quantifies residual myeloma cells in the bone marrow after treatment using multiparametric flow cytometry.

Category overview

Minimal Residual Disease: overview

Securing long-term remission from a blood cancer relies on microscopic vigilance and highly sensitive post-treatment monitoring to ensure your continued health. As an elite subspecialty in our Hematology and Oncology services, Minimal Residual Disease (MRD) testing detects trace amounts of cancer cells—sometimes just one in a million—that standard evaluations leave behind. By leveraging cutting-edge molecular and flow cytometry technology, this crucial diagnostic screening provides definitive reassurance or an early warning of relapse, safely guiding your healthcare provider in proactively adjusting your personalized therapy. Highly regarded for sensitive oncological monitoring among the best diagnostic labs in Dubai and the UAE, DNA Labs guarantees strict patient confidentiality, exceptional analytical accuracy, and incredibly prompt turnaround times. Protect your hematological recovery—book your minimal residual disease testing in UAE, arrange a secure sample collection, or reach out to our specialized medical professionals.

Before booking

Use the test details as a conversation starter

The right diagnostic option depends on your reason for testing and individual circumstances. Check the listed specimen and timing, then confirm any preparation requirements with the ordering clinician or laboratory before collection.